A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Dactolisib (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Sponsors resTORbio
- 05 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Feb 2021.
- 05 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2020 Status changed from not yet recruiting to recruiting.